ATOSSA GENETICS WKN: A2JJ99 ISIN: US04962H5063 Forum: Aktien Thema: Hauptdiskussion

Maxim Group Begins Coverage on Atossa Genetics (ATOS) Maxim Group began coverage on shares of Atossa Genetics (NASDAQ:ATOS) in a report issued on Friday, January 26th, MarketBeat.com reports. The brokerage issued a buy rating and a $2.00 price target on the stock. “Tamoxifen is the most widely used drug to prevent breast cancer recurrence... https://www.thelincolnianonline.com/2018/02/03/atossa-genetics-atos-receives-new-coverage-from-analysts-at-maxim-group-updated.html

Sicher nicht :-))) eher 2,60€ :-)))

Ich sags doch, die 0,26€ kommen bald wieder.

Der Kurs dreht noch

http://nasdaqjournal.com/index.php/2018/02/02/atossa-genetics-inc-nasdaqatos-brief-overview-on-stocks-performances/

http://ir.atossagenetics.com/news/detail/837/atossa-genetics-presents-additional-findings-from-its-phase-1-study-of-oral-endoxifen

Kurs und Volumen zieht so langsam an :-))

http://nasdaqtimes.com/atossa-genetics-inc-atos-prime-game-changers-stocks-for-the-day/

Atossa Genetics (ATOS) Earns Coverage Optimism Score of 0.12 https://stocknewstimes.com/2018/02/02/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-atossa-genetics-atos-share-price.html

https://globenewswire.com/news-release/2018/02/01/1330394/0/en/Atossa-Genetics-Presents-Additional-Findings-from-its-Phase-1-Study-of-Oral-Endoxifen.html

Nachbörslich bei ca 0, 90 USD geschlossen :-)))

Atossa's endoxifen shows much quicker absorption than tamoxifen in early-stage study; shares up 10% after hours https://seekingalpha.com/news/3327574-atossas-endoxifen-shows-much-quicker-absorption-tamoxifen-early-stage-study-shares-10-percent

https://www.analystsbuzz.com/2018/02/01/atossa-genetics-inc-atos-analysis-of-analyst-stock-recommendation/

Sehe ich genau so ! Konferenz ist noch im vollen Gange :-))

Und was soll da herauskommen?

22:30 unserer zeit